These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23980685)

  • 41. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
    Pisati F; Belicchi M; Acerbi F; Marchesi C; Giussani C; Gavina M; Javerzat S; Hagedorn M; Carrabba G; Lucini V; Gaini SM; Bresolin N; Bello L; Bikfalvi A; Torrente Y
    Cancer Res; 2007 Apr; 67(7):3054-63. PubMed ID: 17409412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
    Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
    Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
    Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
    J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas.
    Fack F; Espedal H; Keunen O; Golebiewska A; Obad N; Harter PN; Mittelbronn M; Bähr O; Weyerbrock A; Stuhr L; Miletic H; Sakariassen PØ; Stieber D; Rygh CB; Lund-Johansen M; Zheng L; Gottlieb E; Niclou SP; Bjerkvig R
    Acta Neuropathol; 2015 Jan; 129(1):115-31. PubMed ID: 25322816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutrophils promote the malignant glioma phenotype through S100A4.
    Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
    Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion.
    Shimizu T; Ishida J; Kurozumi K; Ichikawa T; Otani Y; Oka T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Date I
    Mol Cancer Ther; 2019 Apr; 18(4):812-822. PubMed ID: 30872378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
    Keunen O; Johansson M; Oudin A; Sanzey M; Rahim SA; Fack F; Thorsen F; Taxt T; Bartos M; Jirik R; Miletic H; Wang J; Stieber D; Stuhr L; Moen I; Rygh CB; Bjerkvig R; Niclou SP
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3749-54. PubMed ID: 21321221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
    Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
    Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.
    Kang W; Kim SH; Cho HJ; Jin J; Lee J; Joo KM; Nam DH
    Oncotarget; 2015 Sep; 6(29):27239-51. PubMed ID: 26336988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.
    Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM
    Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
    Gabrusiewicz K; Liu D; Cortes-Santiago N; Hossain MB; Conrad CA; Aldape KD; Fuller GN; Marini FC; Alonso MM; Idoate MA; Gilbert MR; Fueyo J; Gomez-Manzano C
    Oncotarget; 2014 Apr; 5(8):2208-20. PubMed ID: 24809734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.
    Hu YL; DeLay M; Jahangiri A; Molinaro AM; Rose SD; Carbonell WS; Aghi MK
    Cancer Res; 2012 Apr; 72(7):1773-83. PubMed ID: 22447568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
    Lu KV; Chang JP; Parachoniak CA; Pandika MM; Aghi MK; Meyronet D; Isachenko N; Fouse SD; Phillips JJ; Cheresh DA; Park M; Bergers G
    Cancer Cell; 2012 Jul; 22(1):21-35. PubMed ID: 22789536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
    Wang J; Svendsen A; Kmiecik J; Immervoll H; Skaftnesmo KO; Planagumà J; Reed RK; Bjerkvig R; Miletic H; Enger PØ; Rygh CB; Chekenya M
    PLoS One; 2011; 6(7):e23062. PubMed ID: 21829586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
    Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
    Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival.
    Li Q; Wijesekera O; Salas SJ; Wang JY; Zhu M; Aprhys C; Chaichana KL; Chesler DA; Zhang H; Smith CL; Guerrero-Cazares H; Levchenko A; Quinones-Hinojosa A
    Clin Cancer Res; 2014 May; 20(9):2375-87. PubMed ID: 24789034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.